Itrotus 200mg Capsule contains Itraconazole, a broad-spectrum triazole antifungal agent indicated for the treatment of various systemic and superficial fungal infections. Itraconazole exerts its antifungal effect by inhibiting the cytochrome P450-dependent enzyme lanosterol 14-α-demethylase, which is essential for the synthesis of ergosterol, a critical component of fungal cell membranes. Disruption of ergosterol synthesis leads to increased membrane permeability and ultimately fungal cell death. Itrotus 200mg is commonly prescribed for conditions such as aspergillosis, histoplasmosis, blastomycosis, onychomycosis, and candidiasis. The capsule formulation ensures optimal bioavailability when administered orally, with absorption enhanced by gastric acidity. Dosage and duration of therapy should be tailored based on the type and severity of infection, patient response, and clinical guidelines. Caution is advised in patients with hepatic impairment or congestive heart failure, and potential drug interactions must be carefully monitored due to itraconazole’s effect on cytochrome P450 enzymes. Adverse effects may include gastrointestinal disturbances, headache, rash, and, rarely, hepatotoxicity. Itrotus 200mg Capsule should be used under strict medical supervision, with regular monitoring of liver function and clinical status to ensure efficacy and safety throughout the treatment course.